

Ewa Kalinka-Warzocha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9475381/publications.pdf>

Version: 2024-02-01

76
papers

8,487
citations

361413

20
h-index

155660

55
g-index

76
all docs

76
docs citations

76
times ranked

12734
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
2	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , 2019, 393, 1819-1830.	13.7	2,347
3	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
4	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	1.6	119
5	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , 2016, 18, 43.	5.0	90
6	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. <i>Blood</i> , 2002, 100, 3037-3040.	1.4	78
7	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1915.	4.1	61
8	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	1.6	55
9	Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. <i>Oncology Letters</i> , 2017, 13, 4433-4444.	1.8	53
10	MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4007-4007.	1.6	40
11	Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. <i>Targeted Oncology</i> , 2020, 15, 301-315.	3.6	37
12	Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma. <i>Journal of Clinical Immunology</i> , 2007, 27, 339-346.	3.8	34
13	The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 61-68.	2.5	32
14	Guidelines for the diagnosis and management of osteoporosis in Poland : Update 2017. <i>Endokrynologia Polska</i> , 2017, 68, 604-609.	1.0	30
15	Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 2047-2057.	2.5	28
16	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
17	Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 1241-9.	1.2	24
18	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 500-507.	2.8	23

#	ARTICLE	IF	CITATIONS
19	Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. <i>Oncology Reports</i> , 2013, 30, 2385-2398.	2.6	23
20	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients. <i>Cancer</i> , 2008, 113, 367-375.	4.1	22
21	Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. <i>Journal of Clinical Oncology</i> , 2016, 34, 193-193.	1.6	20
22	Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 185-193.	2.8	18
23	Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients. <i>Annals of Oncology</i> , 2016, 27, 358-359.	1.2	16
24	First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020, 188, 898-906.	2.5	16
25	Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e65-e75.	2.4	14
26	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. <i>Targeted Oncology</i> , 2021, 16, 357-367.	3.6	13
27	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	4.4	12
28	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 225-240.	2.3	12
29	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
30	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. <i>Tissue Antigens</i> , 2007, 71, 071029015950001-???	1.0	11
31	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. <i>Wspolczesna Onkologia</i> , 2013, 3, 257-262.	1.4	11
32	The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients. <i>Pathology and Oncology Research</i> , 2016, 22, 49-56.	1.9	10
33	Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 28, 67-73.	1.4	10
34	Chemotherapy treatment patterns and neutropenia management in gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 360-367.	5.3	9
35	Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 1222.	3.7	8
36	Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2015, 69, 586-97.	0.1	8

#	ARTICLE	IF	CITATIONS
37	Correlation Between TS, MTHFR, and ERCC1 Gene Polymorphisms and the Efficacy of Platinum in Combination With Pemetrexed First-Line Chemotherapy in Mesothelioma Patients. <i>Clinical Lung Cancer</i> , 2014, 15, 455-465.	2.6	6
38	Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study. <i>Wspolczesna Onkologia</i> , 2015, 3, 214-219.	1.4	6
39	Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. <i>Medical Oncology</i> , 2015, 32, 236.	2.5	6
40	Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2017, 106, 794-800.	1.6	6
41	Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group*. <i>Leukemia and Lymphoma</i> , 2019, 60, 341-348.	1.3	6
42	Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9105-TPS9105.	1.6	6
43	The analysis of ALK gene rearrangement by fluorescence in situ hybridisation in non-small cel lung cancer patients. <i>Wspolczesna Onkologia</i> , 2013, 6, 484-492.	1.4	5
44	Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study. <i>Croatian Medical Journal</i> , 2019, 60, 166-173.	0.7	5
45	420â€...Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. , 2020, , .		5
46	The impact of cancer treatment on cognitive efficiency. <i>European Journal of Psychiatry</i> , 2020, 34, 20-26.	1.3	4
47	Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4526-4526.	1.6	3
48	Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 212-212.	1.6	3
49	Hodgkin Lymphoma in Older Patients- a Retrospective Analysis of the Polish Lyphoma Reasearch Group. <i>Blood</i> , 2014, 124, 1737-1737.	1.4	3
50	Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 603-603.	1.6	2
51	PostÄ™py w diagnostyce i leczenia chorych na chÅ,oniaki nie-Hodgkina. <i>Hematologia</i> , 2015, 6, 31-43.	0.0	2
52	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2011, 118, 880-880.	1.4	2
53	CECOG expertsâ€™ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 75-82.	0.5	1
54	Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland â€“ a report of the Polish Lymphoma Research Group. <i>Archives of Medical Science</i> , 2020, 16, 157-161.	0.9	1

#	ARTICLE	IF	CITATIONS
55	Viral Infection and Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 577514.	2.8	1
56	Long-term analysis of occurrence of malignant lip, oral cavity and pharyngeal cancer in Poland. <i>Nowotwory</i> , 2019, 69, 157-162.	0.3	1
57	Attitudes of Physicians Toward Risk Assessment and Use of Granulocyte-Colony Stimulating Factor (G-Csf) As Primary Prophylaxis (Pp) in Patients (Pts) Receiving Chemotherapy with an Intermediate Risk of Febrile Neutropenia (Fn). <i>Annals of Oncology</i> , 2014, 25, iv522.	1.2	0
58	Leczenie chorych z chłoniakami i współistnieniem zakażeniem wirusami HCV, HBV lub HIV. <i>Acta Haematologica Polonica</i> , 2015, 46, 86-93.	0.3	0
59	Cutaneous melanoma – guidelines for diagnostics and therapy in 2016. <i>Przegląd Dermatologiczny</i> , 2016, 1, 1-18.	0.1	0
60	Population morbidity in elderly lung cancer patients from Poland with specific trends in elderly women. <i>Przegląd Menopauzalny</i> , 2019, 18, 161-165.	1.3	0
61	Immuntherapie des Bronchialkarzinoms: Mehr als PD-L1-Marker. <i>Karger Kompass Onkologie</i> , 2020, , 5-15.	0.0	0
62	Immunogenicity of Influenza Vaccination in Patients with Non-Hodgkin Lymphoma: Final Report after Two Epidemic Seasons.. <i>Blood</i> , 2006, 108, 4598-4598.	1.4	0
63	Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers.. <i>Blood</i> , 2009, 114, 1702-1702.	1.4	0
64	Chemotherapy (CT) treatment patterns and neutropenia management in gastric cancer patients (pts) receiving myelosuppressive chemotherapy in Europe.. <i>Journal of Clinical Oncology</i> , 2013, 31, 128-128.	1.6	0
65	Zastosowanie wemurafenibu u chorych na uogólnionego czerniaka z obecnością mutacji w genie BRAF – wybrane przypadki kliniczne. <i>Nowotwory</i> , 2014, 64, 1-19.	0.3	0
66	Human Leukocyte Antigen-G Polymorphisms Influence Clinical Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1643-1643.	1.4	0
67	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1642-1642.	1.4	0
68	Immune response in breast cancer brain metastases (BM) and their microenvironment.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22112-e22112.	1.6	0
69	Czerniaki skóry – zasady postępowania diagnostyczno-terapeutycznego w 2016 roku. <i>Nowotwory</i> , 2016, 65, 501-516.	0.3	0
70	The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?. <i>Journal of Clinical Oncology</i> , 2016, 34, 5024-5024.	1.6	0
71	Wyniki leczenia wemurafenibem chorych na zaawansowanego czerniaka w ramach programu lekowego w Polsce. <i>Nowotwory</i> , 2016, 66, 118-126.	0.3	0
72	Does diabetes alter the risk of neoplasms? Real-world data analysis in Poland: incidence rates for selected neoplasms in patients with diabetes. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 435-437.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Najważniejsze doniesienia dotyczące nowotworów układowych z dorocznej konferencji Amerykańskiego Towarzystwa Onkologii Klinicznej w 2016 roku. <i>Hematologia</i> , 2016, 7, 117-127.	0.0	0
74	Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, e16537-e16537.	1.6	0
75	Niedokrwiistość u chorych na nowotwory – zalecenia grupy ekspertów. Aktualizacja 2020 r. <i>Oncology in Clinical Practice</i> , 2020, 16, 261-269.	0.1	0
76	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in Poland: analysis of patient series and practical guidelines for breast surgeons. <i>Archives of Medical Science</i> , 2020, , .	0.9	0